March 16, 2026
Restricted anti-infective drugs may be approved by the ID consult services or by the Carolina Antimicrobial Stewardship Program (CASP). Restricted anti-infectives initiated by the ID medicine service (MDK) do not require approval.
February 28, 2026
Duration recommendations are provided as a general guideline for therapy (IV or PO) with a goal of minimizing unintended consequences to the patient (e.g., precipitating C. difficile colitis, development of resistant pathogens, organ dysfunction). Patient-specific factors should influence duration decisions and transition to oral therapy.
November 13, 2025
November 2, 2025
Immediate guidance for the initial diagnosis and management of malaria at UNC Hospitals. Infectious Diseases consultation is recommended when malaria is diagnosed or strongly suspected. key words: malaria, antimalarial, artesunate, dengue, Chikungunya, P. falciparum, P. vivax, P. ovale
September 22, 2025
c. diff, c. difficile, fidaxomicin, bezlotoxumab, vancomycin, Clostridioides difficile, CDI, diarrhea, Clostridium difficile
July 25, 2025
Certain azole antifungal drugs require therapeutic drug monitoring (TDM) due to important exposureresponse relationships and significant pharmacokinetic variability. This guideline outlines recommendations for the TDM of itraconazole, posaconazole, voriconazole, and isavuconazole.
July 11, 2025
Antimicrobial susceptibility organisms submitted to the University of North Carolina Hospitals Microbiology Laboratory between 1/1/2024 and 12/31/2024. Antibiograms help guide the clinician and pharmacist in selecting the best empiric antimicrobial treatment in the event of pending microbiology culture and susceptibility results.
March 1, 2025
isolation, epidemiology, infection, prevention
September 26, 2024
August 19, 2024
This document provides guidance in management, including diagnostic evaluation, antimicrobial therapy, procedural management, and disposition, of children with community-acquired pneumonia (CAP). It is not intended to replace clinician judgment in individual cases; however, it should apply to the vast majority of patients diagnosed with CAP.
August 1, 2024
Hospital-acquired pneumonia (HAP) and Ventilator-associated pneumonia (VAP) are healthcare-acquired conditions with significant risk of morbidity and mortality. Hospitalized patients may have multiple risk factors for pneumonia, such as recumbent position, impaired cough reflex, procedural sedation, immunocompromised status, and/or artificial airways. Prompt recognition of pneumonia in hospitalized patients can prevent serious complications. However, cultures of respiratory secretions are difficult to obtain in patients without an artificial airway or have limited specificity in patients with an endotracheal tube or tracheostomy tube. This guideline document will address the diagnosis and treatment of HAP and VAP in pediatric patients at UNC Children’s. Guidelines for HAP and VAP prevention are maintained separately.
February 9, 2024
CRE, OXA-48, KPC, ceftazidime-avibactam, meropenem-vaborbactam, carbapenem resistant, imipenem-relebactam, cefidericol, B-lactam